No Data
No Data
Subdued Growth No Barrier To Changzhou Qianhong Biopharma CO.,LTD (SZSE:002550) With Shares Advancing 36%
Qianhong Pharmaceutical: Report for the third quarter of 2024
Changzhou Qianhong Biopharma (002550.SZ) announced its performance for the first three quarters, with a net income of 0.31 billion yuan, a year-on-year increase of 56.47%.
Changzhou Qianhong Biopharma (002550.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...
Changzhou Qianhong Biopharma (002550.SZ): The net income for the third quarter is 0.127 billion yuan, a year-on-year increase of 60.84%.
Gelonghui, October 17th | Changzhou Qianhong Biopharma (002550.SZ) announced its third quarter report of 2024, with a revenue of 0.352 billion yuan, a decrease of 13.97% year-on-year; a net income attributable to shareholders of the listed company of 0.127 billion yuan, an increase of 60.84% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of 48.7781 million yuan, a decrease of 9.80% year-on-year; basic earnings per share of 0.1015 yuan.
Qianhong Pharmaceutical: 2024-035 Qianhong Pharmaceutical: Performance forecast for the first three quarters of 2024
Changzhou Qianhong Biopharma CO.,LTD's (SZSE:002550) Market Cap up CN¥387m Last Week, Benefiting Both Retail Investors Who Own 49% as Well as Insiders
No Data
No Data